Loading clinical trials...
Loading clinical trials...
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or h...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Takeda
NCT07223944 · Gaucher Disease Type 1
NCT05992532 · Gaucher Disease, Acid SphingoMyelinase Deficiency
NCT03333200 · MLD, Krabbe Disease, and more
NCT06573723 · Rare Diseases, Amyloidosis, and more
NCT05487599 · Gaucher Disease, Gaucher Disease, Type 1
Konan
Kōnan, Aichi-ken
Nagoya
Nagoya, Aichi-ken
Kitakyushu
Kitakyushu, Fukuoka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions